| 描述信息 |
Many patient-derived tumor models have emerged recently. However, their potential to guide personalized drug selection remains unclear. Here, we report a novel non-small cell lung cancer patient-derived tumor-like cell clusters (PTCs) that could accomplish 100-5,000 drug testing within 10 days. Over 270 PTC models have been established with an 81% success rate. PTCs contain primary tumor epithelium self-assembled with endogenous stromal cells, and show a high degree of similarity to the original tumors in phenotypic and genotypic features. More importantly, PTC drug-testing assays reveal an overall consistency of 89% in predicting the clinical outcomes of 51 recruited patients, and an accuracy of 98.1% in discriminating the complete/partial response group from the progressive disease group. CD8+ T cells assembled in PTCs show the heterogeneity in expansion and cytotoxicity responses upon the anti-PD1 treatment. Together, these data indicate that PTC is a promising in vitro preclinical model for personalized medicine and basic research. |
